PMC4743131_01
QLQ-C30 Functional scales (a) and combined symptoms score (b)
40364_2016_56_Fig1_HTML.jpg
PMC4743131_01_40364_2016_56_Fig1_HTML.jpg
Fig1
Symptoms and quality of life were assessed every 4 weeks by EORTC QLQ-C30 (Fig. 1a and b), BFI (Fig. 2), MPN-SAF (Fig. 3), and
MPN-SAF
40364_2016_56_Fig3_HTML.jpg
PMC4743131_01_40364_2016_56_Fig3_HTML.jpg
Fig3
Skin rash prior to therapy with Ruxolitinib (a) and 24 weeks post therapy (b)
40364_2016_56_Fig4_HTML.jpg
PMC4743131_01_40364_2016_56_Fig4_HTML.jpg
Fig4
Flushing resolved and cutaneous manifestations markedly improved (Fig. 4a and b).